Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
Dear editor We have read with great interest the paper by Tang and Chen 1 published in the most recent issue of the International Journal of Nanomedicine, in which the authors describe the protocol by which scientists constructed the ideal BRAF VE -modeled structure through homology modeling and introduced the method of structure-based docking or virtual screening from a virus papiloma nivel 3 compound database.
They concluded that BRAF VE has a quite prominent structural or conformational variation when compared to the wild-type BRAF protein by matrix of root mean square fluctuation and principal component analysis.
On the basis of structure-based virtual screening, ligand-based quantitative structure activity cancer colon braf models, and molecular dynamics simulation, we recommend aknadicine and 16beta-hydroxys-vindolinine N-oxide as potent compounds for developing novel inhibitors in the future.
Extracellular signals such as hormones, cytokines, and various growth factors interact with their receptors to activate the small G-proteins of the RAS family.
Please wait while your request is being verified...
BRAF-mutated tumors have a poor response to traditional chemotherapy and a poor prognosis in melanoma, thyroid, and colon cancers. The approach of targeting oncogenic kinases has been successful in the treatment of cancers with activating mutations in the kinase gene that drives their progression.
It is likely that our evolving understanding of BRAF genetics and signaling will allow further personalization of cancer therapy with the goal of improving clinical responses.
We are confident that the results reported Tang and Chen 1 have brought progress to the field, but targeting a malignant cell with a monotherapy protocol is expected to fail and thus lead to clinical relapse of the disease.
Thus, combination therapy is likely to be the most effective management plan for the treatment of BRAF-mutated tumors.
Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
Many BRAF-specific inhibitors display a cytostatic response inducing senescence and are susceptible to acquired resistance. Therefore, combination with traditional chemotherapeutic agents seems to cancer colon braf more effective than either treatment alone.
Footnotes Author contributions All authors have cancer colon braf substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in either drafting the communication or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Disclosure The authors report no conflicts of interest in this work. References 1. Int J Nanomedicine.
Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front Oncol. Cancer colon braf generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
Article Introduction Colorectal cancer CRC is the third most common cancer in men and the second most common in women. Although screening, addressability and increased awareness have augmented the number of cases in the non-metastatic setting, approximately one in four individuals with CRC will be diagnosed in stage IV.
BMC Cancer. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Această cale de transducție a semnalului este activată constitutiv în numeroase tipuri de tumori maligne umane de obicei ca urmare a unor mutații ale oncogenelor KRAS și BRAF1;2;3. Mutațiile genei BRAF pot fi de două tipuri: moștenite ale liniei germinale — asociate cu sindromul cardiofaciocutanat — condiție genetică rară caracterizată prin defecte cardiace, retard mental și un cancer colon braf facial distinctiv; dobândite somatice — asociate cu forme diferite de cancer limfom non-Hodgkin, cancer colorectal, melanom malign, cancer tiroidian papilar, cancer pulmonar altul decât cel cu celule mici —NSCLC, cancer ovarian 4;5. Până în prezent au fost identificate peste 50 mutații distincte ale genei BRAF multe dintre acestea fiind responsabile de creșterea activității BRAF de 1. Consecința acestei mutații punctiforme missens este că situsul de activare al protein-kinazei devine expus în mod normal fiind ascuns într-o pungă hidrofobăceea ce conduce la o activare constitutivă BRAF.